SGN22E-003
08 Jun 2021
EV-302
NCT04223856
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer.
Astellas Pharma Global Development, Inc.
Cancer Type | Other |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | Urothelial |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2020-03-30 |
Anticipated End Date | 2023-11-22 |
Hospital | Lyell McEwin Hospital |
---|---|
Clinical Trial Coordinator | Andy Phay |
andy.phay@sa.gov.au | |
Phone | 08 8282 0833 |
Principal Investigator | Dr Mark McGregor |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs